Albeit numerous trials, only a few were clinically approved as AD therapeutics, including long-standing acetylcholinesterase (AchE) inhibitors (donepezil, rivastigmine, galantamine), glutamate regulators (memantine), and newly added anti Aβ monoclonal antibodies. The gene discussed is ACHE; the disease is Alzheimer disease.